À¶Ý®ÊÓƵ

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Trial ID or NCT#

NCT06400303

Status

recruiting iconRECRUITING

Purpose

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis

Official Title

KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

David Fiorentino, MD, PhD
David Fiorentino, MD, PhD
Dermatologist, Autoimmune disease specialist
Professor of Dermatology

Contact us to find out if this trial is right for you.

Contact

Kyverna Therapeutics, Inc.
510-925-2484

View on